摘要
目的评价尼可地尔对经皮冠状动脉介入(percutaneous coronary intervention,PCI)治疗后再发心绞痛合并2型糖尿病患者的疗效和安全性。方法选取PCI治疗后再发心绞痛合并2型糖尿病患者60例,随机(电脑随机数字表法)分为两组,两组均给予常规治疗,试验组使用尼可地尔,对照组在常规治疗的基础上给予单硝酸异山梨酯片治疗。结果治疗1周后,试验组心绞痛发作次数[(6.5±2.8)次vs.(10.2±4.8)次,P<0.05]、持续时间[(1.5±0.9)min vs.(2.4±2.3)min,P<0.05]、显效率[80.0%(24/30)vs.53.3%(16/30),P<0.05],心电图改善[80.0%(24/30)vs.40%(12/30),P<0.05]均优于对照组,差异有统计学意义(P<0.05)。试验组出现轻中度头痛2例,对照组出现轻中度头痛4例,两组比较差异有统计学意义(P<0.05)。两组均无明显低血压发生,对血糖也无明显影响。结论尼可地尔能明显降低冠状动脉粥样硬化性心脏病(冠心病)合并2型糖尿病患者PCI治疗后再发心绞痛的发生风险。
Objectives To observe the efficacy and safety of nicorandil in patients with recurrent angina pectoris complicated with type 2 diabetes after percutaneous coronary intervention （PCI）. Methods Totally 60 patients with recurrent angina pectoris complicated with type 2 diabetes after PCI were selected in this study. They were randomly divided into two groups：experimental group and control group. Each group was given the conventional therapy. Experimental group used nicorandil and control group used isosorbide mononitrate on the basis of routine therapy. Results After 1 week＇s treatment, angina attack frequency （6.5±2.8 vs. 10.2±4.8,P〈0.05）, duration [（1.5±0.9） min vs. （2.4±2.3） min,P〈0.05 ], efficiency [ 80.0% （24/30） vs. 53.3% （16/30）, P〈0.05 ] and improvement in electrocardiogram [ 80,0% （24/30） vs. 40% （12/30）, P〈0.05] in experimental group were significantly better than those in control group. There were 2 cases with mild-to-moderate headache in experimental group, and 4 in control group. The difference between them was statistically significant （P〈0.05）. There were no significant hypotension or obvious effect on blood glucose in the two groups. Conclusions Nieorandil can significantly reduce the occurrence risk of recurrent angina pectoris in patients with coronary heart disease complicated with type 2 diabetes after PCI.
出处
《岭南心血管病杂志》
2014年第3期300-302,共3页
South China Journal of Cardiovascular Diseases
